FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible NPM1 Mutation

On October 24, the FDA approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.

For more information, read the FDA announcement and the Syndax Pharmaceuticals press release.

Posted on 10/27/2025